Assessment of Kidney Transplant Rejection Risk
Kidney transplant rejection risk is assessed through a multi-component immunologic evaluation that includes HLA matching, crossmatch testing, donor-specific antibody (DSA) screening, and post-transplant monitoring protocols.
Pre-Transplant Immunologic Assessment
HLA Matching and Antibody Testing
The foundation of rejection risk assessment begins with comprehensive HLA typing and antibody screening. Flow cytometry or anti-human globulin (AHG)-enhanced complement-dependent cytotoxicity (CDC) crossmatch testing should be performed for all patients 1. A positive crossmatch with IgG antibodies to HLA antigens is a contraindication to transplantation, while IgM-positive crossmatches are not contraindications 1.
HLA-DQ mismatches deserve particular attention, as they are strongly associated with de novo DSA development and antibody-mediated rejection (ABMR). More than 50% of patients with 2 HLA-DQ mismatches in their first graft become highly sensitized upon graft failure, significantly more than mismatches at other HLA loci 2. Recipients with HLA-DQ mismatches show increased risk of graft loss even after adjusting for HLA-A, -B, and -DR matching 2.
Panel Reactive Antibody (PRA) Monitoring
Patients should have sera tested regularly (monthly, bimonthly, or quarterly) for antibodies to HLA antigens 1. When performing donor-specific crossmatches, historically reactive sera (reflecting immune memory), current sera, and immediately pre-transplant sera must all be tested 1. This is critical because patients may display an anamnestic immune response leading to accelerated rejection despite a negative pre-transplant crossmatch with current sera alone.
For highly sensitized patients (PRA ≥50%), avoiding blood transfusions helps reduce PRA levels; if transfusion is necessary, leukocyte-poor blood should be used 1.
Post-Transplant Monitoring Protocol
Biochemical Surveillance
Serum creatinine should be measured according to a strict schedule 3:
- Daily for 7 days or until hospital discharge
- 2-3 times weekly for weeks 2-4
- Weekly for months 2-3
- Every 2 weeks for months 4-6
- Monthly for months 7-12
- Every 2-3 months thereafter
Urine protein excretion should be measured 3:
- Once in the first month (baseline)
- Every 3 months during the first year
- Annually thereafter
Donor-Specific Antibody Monitoring
Post-transplant DSA surveillance is essential for identifying antibody-mediated rejection risk. The presence of circulating DSAs is a key diagnostic criterion for ABMR in the Banff classification 4. De novo DSA development, particularly against HLA-DQ antigens, occurs in a substantial proportion of patients and is associated with inferior graft outcomes 2. Studies show that 77% of patients with de novo DSA had antibodies targeting donor HLA-DQ, with significantly increased risk for ABMR, transplant glomerulopathy, and graft loss 2.
Immunosuppression Drug Monitoring
Calcineurin inhibitor (CNI) blood levels should be measured 3:
- Every other day during the immediate post-operative period until target levels are reached
- Whenever there is a medication change or patient status change affecting blood levels
- Whenever kidney function declines suggesting nephrotoxicity or rejection
For cyclosporine, monitor using 12-hour trough (C0), 2-hour post-dose (C2), or abbreviated AUC. For tacrolimus, use 12-hour trough (C0) 3.
Biopsy Indications for Rejection Assessment
Kidney allograft biopsy is recommended before treating acute rejection unless biopsy will substantially delay treatment 3. Specific indications include 3:
- Persistent, unexplained increase in serum creatinine
- Serum creatinine not returning to baseline after treatment of acute rejection
- Every 7-10 days during delayed graft function
- Expected kidney function not achieved within 1-2 months post-transplant
- New onset or unexplained proteinuria >3.0 g per gram creatinine
Imaging Assessment
Ultrasound should be included as part of the assessment of kidney allograft dysfunction 3. Ultrasound is the first-line modality for evaluating transplant dysfunction, assessing size, echotexture, hydronephrosis, peritransplant fluid collections, and vascular patency using color Doppler 5. It offers advantages of portability, no radiation exposure, and avoidance of nephrotoxic contrast agents 5.
Novel Risk Stratification Tools
Emerging evidence supports pre-transplant transcriptomic profiling for rejection risk assessment. A validated 29-gene signature algorithm can stratify patients as high or low risk for early acute rejection (EAR) within 60 days post-transplant, with sensitivity of 0.67 and specificity of 0.78 6. High-risk patients identified by this method have a 7-fold increased odds of EAR compared to low-risk patients 6.
Key Risk Factors to Identify
The most significant risk factors for rejection include 7, 8:
- Presence of donor-specific antibodies (adjusted OR: 2.68 for 2-year rejection)
- Pre-transplant DSA against HLA class II (substantially increases TCMR incidence to 28% at 1 year vs. 13% without preDSA)
- Younger recipient age
- Deceased donor transplant
- Higher number of HLA mismatches, particularly HLA-DQ
- Post-transplant infections (blood infections, Pseudomonas aeruginosa, BK virus)
Critical Pitfalls to Avoid
Do not rely solely on current sera for crossmatching—historical sera with the highest PRA must be tested to detect immune memory that could trigger accelerated rejection 1.
Do not ignore HLA-DQ matching—focusing only on HLA-A, -B, and -DR misses a critical predictor of de novo DSA formation and long-term graft survival 2.
Do not assume all positive crossmatches are contraindications—distinguish between IgG (contraindication) and IgM (not a contraindication) antibodies 1.
Do not delay biopsy when rejection is suspected—early histologic confirmation allows appropriate treatment before irreversible damage occurs 3.